A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy

As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Eric J., Cao, Xuezhi, Moon, Benjamin, Bae, Joonbeom, Sun, Zhichen, Liu, Zhida, Fu, Yang-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119481/
https://www.ncbi.nlm.nih.gov/pubmed/33986267
http://dx.doi.org/10.1038/s41467-021-22980-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119481/
https://www.ncbi.nlm.nih.gov/pubmed/33986267
http://dx.doi.org/10.1038/s41467-021-22980-w

Ejemplares similares